Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

Clinical Cancer Research

Volumn 13, Issue 24, 2007, Pages 7487-7495

  Kamat, Aparna A ^a   Merritt, William M ^a   Coffey, Donna ^b   Lin, Yvonne G ^a   Patel, Pooja R ^a   Broaddus, Russell ^a   Nugent, Elizabeth ^a   Han, Liz Y ^a   Landen Jr , Charles N ^a   Spannuth, Whitney A ^a   Lu, Chunhua ^a   Coleman, Robert L ^a   Gershenson, David M ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; DOCETAXEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MONOTHERAPY; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS HORN;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MICE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; TAXOIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37549006796     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1017     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology - mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005;15:710-26.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
7. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
8. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000;105:17-9.
9. Sood AK, Fletcher MS, Zahn CM, et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 2002;1:661-4.
10. Talvensaari-Mattila A, Soini Y, Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol 2005;26:81-7.
11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
13. Sivridis E, Giatromanolaki A, Anastasiadis P, et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 2002;196:416-22.
14. Salvesen HB, Iversen OE, Akslen LA. Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 1988;77:1140-4.
15. Chen CA, Cheng WF, Lee CN, et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol Oncol 2001;80:207-12.
16. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24.
17. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-14.
18. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. [Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors]. Nippon Sanka Fujinka Gakkai Zasshi 1985;37:1103-11.
19. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972;114:1012-9.
20. Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209-17.
21. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8.
22. Smith SK. Angiogenesis and reproduction. BJOG 2001;108:777-83.
23. Holland CM, Day K, Evans A, Smith SK. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003;89:891-8.
24. Sanseverino F, Santopietro R, Torricelli M, et al. pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther 2006;5:84-8.
25. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001;80:181-8.
26. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
27. Kaku T, Kamura T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer 1997;80:741-7.
28. Kirschner CV, Alanis-Amezcua JM, Martin VG, et al. Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 1996;174:1879-82.1996.
29. Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006;66:3303-9.
30. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
31. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153:543-53.
32. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54.
33. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-α agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006;5:13.
34. Dai D, Holmes AM, Nguyen T, et al. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res 2005;65:9517-24.
35. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351-4.
36. Berry KK, Siegal GP, Boyd JA, Singh RK, Fidler IJ. Development of a metastatic model for human endometrial carcinoma using orthotopic implantation in nude mice. Int JOncol 1994;4:1163-71.
37. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. In: 2005 ASCO Annual Meeting Proceedings, Atlanta (GA), 2005.
38. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006;102:140-4.